Value profile for Malaria vaccines and monoclonal antibodies Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decade…

With #malaria #vaccines on the market, we're developing next-gen vaccines and monoclonal antibodies to bring us closer to #malariaeradication. Read about the @who.int-commissioned impact value assessment of malaria vaccines and prophylactic #mAbs in the pipeline: shorturl.at/CgG0J

📰 NEW in @washingtonpost.com "We finally may be able to rid the world of mosquitoes. But should we?" Featuring insight from HC Research Director, Gregory E. Kaebnick. 🧠🧬

👉 𝐑𝐄𝐀𝐃: wapo.st/3SzwPVd

#IntentionalExtinction #GeneEditing #MalariaEradication